Revcovi?

Revcovi is the brand name for eftrenonacog alfa, a recombinant factor IX Fc fusion protein. It’s a long-acting factor IX replacement used to prevent bleeding episodes in people with hemophilia B (factor IX deficiency).

Key points:
- What it does: replaces missing factor IX to help blood clotting. The Fc fusion extends its half-life, so you don’t need as many infusions as with standard factor IX products.
- Indications: routine prophylaxis to prevent bleeding in adults and children with hemophilia B; it’s also used to treat bleeds as prescribed.
- How it’s given: intravenous (IV) infusion. Dosing is individualized based on body weight, bleeding history, and how your body processes the drug.
- Dosing frequency: many patients can be dosed about once a week or less frequently (e.g., every 14 days) depending on pharmacokinetics and control of bleeding. Your healthcare provider will tailor this for you.
- Safety and side effects: common reactions may include injection-site reactions, headaches, or nausea. More serious risks include development of inhibitors to factor IX and, rarely, allergic reactions or thrombotic events. People with known allergies to factor IX products or to any excipients should not use it.
- Special considerations: regular monitoring for factor IX activity and any signs of inhibitors is important. Use during pregnancy or breastfeeding should be discussed with a clinician. If you have liver disease, a clinician may monitor closely.

If you’d like, I can:
- Compare Revcovi with other hemophilia B therapies (e.g., dosing, pros/cons).
- Provide a more detailed overview of dosing concepts (based on general PK principles).
- Look up specific patient-education points (storage, administration steps) or any safety notes.

What would you like to know about Revcovi?